A detailed history of Keybank National Association transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Keybank National Association holds 4,620 shares of PCVX stock, worth $513,882. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,620
Previous 4,202 9.95%
Holding current value
$513,882
Previous $287,000 21.25%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 31, 2024

BUY
$60.06 - $78.77 $25,105 - $32,925
418 Added 9.95%
4,620 $348,000
Q1 2024

May 14, 2024

SELL
$59.79 - $81.05 $8,011 - $10,860
-134 Reduced 3.09%
4,202 $287,000
Q4 2023

Feb 13, 2024

SELL
$45.35 - $63.41 $10,385 - $14,520
-229 Reduced 5.02%
4,336 $272,000
Q3 2023

Nov 08, 2023

BUY
$46.0 - $53.1 $24,012 - $27,718
522 Added 12.91%
4,565 $232,000
Q2 2023

Aug 01, 2023

BUY
$34.66 - $54.07 $140,130 - $218,605
4,043 New
4,043 $201,000

Others Institutions Holding PCVX

About Vaxcyte, Inc.


  • Ticker PCVX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,315,100
  • Market Cap $6.6B
  • Description
  • Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...
More about PCVX
Track This Portfolio

Track Keybank National Association Portfolio

Follow Keybank National Association and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Keybank National Association, based on Form 13F filings with the SEC.

News

Stay updated on Keybank National Association with notifications on news.